In tumor xenograft models, using human pancreatic cancer cell lines, CXCL8 expression was correlated with a preferential expansion of CXCR2+CD68+ macrophages, which significantly led to the decreased efficacy of anti-PD1 therapy [39]. The gene discussed is CXCR2; the disease is familial pancreatic carcinoma.